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ABSTRACT
ASSANI, KAIVON. M.S.B.M.E. Department of Biomedical, Industrial and Human Factors
Engineering, Wright State University, 2018. M1 to M2 Macrophage Induction Using
Retinoic Acid and Mesenchymal Stem Cells Loaded on An Electrospun Pullulan/Gelatin
Scaffold to Promote Healing of Chronic Wounds
Modulation of macrophage polarization is required for effective tissue repair and
regenerative therapies. Conversion of macrophages from inflammatory M1 to fibrotic M2
phenotype could help in diseases such as chronic wound which are stuck in inflammatory
state. During the inflammatory phase, macrophages are of the inflammatory phenotype
(M1) and distribute pro-inflammatory cytokines including TNF-α and IL1β which are
microbicidal and recruit/activate cells. In normal wound healing macrophages then switch
to a fibrotic phenotype (M2) promoting wound closure by angiogenesis, and matrix
deposition. Chronic wounds are a major biological and financial burden to both patients
and the health care system, costing over $25 billion to Medicare annually. Natural wound
healing proceeds through several largely overlapping phases that involve an inflammatory
response and associated cellular migration, proliferation, matrix deposition, and tissue
remodeling. The initial stages of the inflammatory response are dominated by neutrophils
followed soon after by macrophages, which become prominent at the wound site. A
sustained inflammation is an important aspect in the disruption of the normal healing
process that can lead to a chronic condition. The chronic conditions start when the highly
iii

phagocytic M1 macrophages are done removing any infected or non-functional cells, and
any damaged matrix or foreign debris and do not differentiate into an M2 phenotype.
Thus, inducing these sustained M1 macrophages to differentiate into an M2 phenotype
should correct this condition, and has been shown to improve wound healing.
We suggest simultaneously using retinoic acid (RA) and mesenchymal stem cells
(MSCs) to promote M1 to M2 transition. RA and MSCs have both shown to promote M1
to M2 transition, and in addition, MSCs can promote wound regeneration. We
hypothesize that treating M1 macrophages with retinoic acid and mesenchymal stem
cells loaded on a pullulan/gelatin scaffold will promote M1 to M2 conversion. To
facilitate this, we developed an electrospun hydrogel consisting of 75% pullulan and 25%
gelatin and crosslinked with 1:70 ethylene glycol diglycidyl ether (EGDE) in ethanol
(EtOH). Pullulan was chosen due to its ability to quench reactive oxygen species and
reduce inflammation, as well as for its excellent mechanical properties. While gelatin was
added to provide functional motifs for cellular attachment. The scaffold composition was
determined via FTIR. The scaffold degraded to approximately 80% after 14 days, and
approximately 38% of the drug was released after 7 days. Scaffold nanofibers were
determined to 328nm (±47.9) in diameter. RA and MSCs were directly loaded and used to
treat M1 THP1 cell derived macrophages to induce polarization. qPCR shows a reduction
of M1 markers TNFα and IL1β, and an increase of M2 marker CCL22 after 2 days of scaffold
treatment, suggesting successful M1 to M2 transition.
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CHAPTER I
Introduction

Macrophages are critical immune cells involved in controlling infection, inflammation
and disease. These cells are multifunctional and can be highly plastic, able to switch
between phenotypic expression patterns depending on environmental ques [1].
Macrophages play a role in both the adaptive and innate immune system. Their role in
the adaptive immune system involves being antigen presenting cells. In addition, their
induction of regulatory T cells plays a role for tissue regeneration and disease prevention
[2]. Here we will mainly focus on their role within the innate immune system, as it relates
to their response to bacterial infection and tissue injury.
During wound healing macrophages migrate to the site of injury from the blood as
well as from the surrounding tissues. Macrophages initially become inflammatory to
promote the clearance of infection and debris. They secrete matrix metalloproteinases
(MMPs) to remove damaged cells and make way for scar formation. Normally
macrophages contribute to disease prevention, infection removal, debris removal, tissue
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healing and regulation, however if regulation of wound healing does not occur
appropriately a chronic inflammatory condition can develop [3]. This would promote a
consistent M1 phenotype for the macrophages.
Macrophages are commonly described as one of two phenotypes inflammatory
M1 or fibrotic/anti-inflammatory M2 [4]. Regulation between M1 and M2 phenotypes is
critical to manage infection and disease [5]. M1 macrophages produce inflammatory
cytokines which recruit immune cells, such a neutrophils, promoting further
inflammation. During normal healing processes M1 macrophages are predominant to
removing debris, infection and damaged cells. M2 macrophages down regulate
inflammation and promote tissue deposition. Dysregulation of M1 or M2 expression has
been associated with inflammatory diseases including chronic infection, chronic wounds
(i.e., diabetic, pressure and venous ulcers), asthma, cancer, Parkinson’s, chronic
obstructive pulmonary disease, atherosclerosis, Alzheimer’s disease and cancer [6]–[12].
This study aims to promote conversion of M1 macrophages to M2 macrophages which
could serve as a treatment for chronic inflammatory diseases, which show high M1
macrophage populations.
In our project we developed an electrospun hydrogel composed of pullulan and
gelatin, loaded with retinoic acid (RA) and adipose derived mesenchymal stem cells
(ADMSCs) to promote M1 to M2 conversion in macrophages. Both RA and ADMSCs have
been shown to polarize macrophages to M2 phenotype as well as fibrosis. This patch was
designed with chronic wounds in mind taking into account studies which have used
pullulan, gelatin, RA and MSCs in separate experiments to improve chronic wound healing
2

[13]–[16]. This is the first time each of these has been used together. Such a therapeutic
could improve healing of chronic wounds which affect over 8.2 million patients on
Medicare and cost over 25 billion dollars per year [17], [18].
When macrophages arrive at the site of inflammation they are exposed to
inflammatory stimulants such as lipopolysaccharide (LPS) and interferon gamma (IFN-γ)
which causes polarization towards the M1 phenotype. These macrophages then further
stimulate inflammation by releasing inflammatory cytokines including TNF-α and IL1β, as
well as other microbicidal molecules such as MMPs. At the end of the inflammatory
phase, M1 macrophages differentiate into M2 macrophages, which express antiinflammatory cytokines, including CCL18 and CCL22.
Macrophage role in adaptive immunity also depends on their polarization. M1
macrophages are antigen presenting cells which recruit and communicate with T helper
Th1 cells, while M2 macrophages coordinate Th2 cell recruitment and suppress Th1 cell
response. Macrophages play a vital role in controlling infection, disease, regeneration and
wound healing, and by promoting M1 to M2 transition inflammatory diseases be
ameliorated [19]. [20], [21]
We hypothesize a novel combination of MSCs and RA loaded with electrospun
nanofiber scaffold made of pullulan and gelatin as a therapeutic to promote M1 to M2
induction. Research has shown that ADMSCs and RA improve M1-M2 transition and
wound repair, however, their joint effect has not been documented [13], [14], [22], [23].
Pullulan was chosen because it offers good biocompatibility and anti-inflammatory
3

properties by quenching reactive oxygen species (ROS) [15], [24]–[26]. Gelatin has good
biocompatibility and binding motifs for cellular adhesion, making it an ideal copolymer.
Gelatin is extensively used in biomedical engineering and has been approved for use in
drug delivery and wound healing [27]. After electrospinning, ethylene glycol Diglycidyl
ether (EGDE) was used to crosslink the nanofibers. It can bind to the hydroxyl group on
both pullulan and gelatin to improve mechanical strength and delay degradation. Pullulan
and gelatin has been shown to be effective scaffolds for wound healing [28]–[30]. This is
the first study which combines MSCs, RA, pullulan and gelatin. Here we verify the
structure and composition of the scaffold using FTIR and SEM, examine degradation and
release rate, and evaluate the potential to modulate macrophage polarity from M1 to M2
phenotype using qPCR.
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CHAPTER II
Background

2.1 Macrophages
Macrophages are immune cells derived from the myeloid lineage. They are
located throughout the body and stationed in specific tissues to help recycle dead cells
and clean away foreign debris and material. When there is no tissue damage,
macrophages help to recycle apoptotic cells and around 200 billion dead erythrocytes per
day [31]. This process is known as phagocytosis, and it is locally controlled in response to
specific ques [32]. Macrophages also regulate the inflammatory response which is part of
the response to cell death and debris. Imbalances in the inflammatory process result in
cell and tissue damage such as in chronic inflammatory disease [33]-[34].

2.1.1 Macrophage Development and Specialization
Macrophages are replenished by bone marrow derived monocytes; however,
tissue-specific macrophages may rely on a self-renewal process. Tissue specific
5

macrophages that self-renew originate from embryonic macrophages. Bone marrowderived macrophages, on the other hand, provide macrophages on demand from
monocyte precursors. Bone marrow-derived macrophages come from hematopoietic
stem cells, which give rise to Ly6Chi monocytes. These require CCR2 to be able to exit the
bone marrow and enter the blood stream. Fate mapping activates important reporter
genes to determine downstream lineage. Bone marrow monocytes can differentiate into
many types including tumor-associated macrophages, monocyte-derived dendritic cells
(e.g., during colitis, lung infection, etc.), effector monocytes (e.g., for colitis, peritonitis,
liver disease), monocyte-derived macrophage (e.g., for tissue injury, such as skin, muscle,
heart and central nervous system), and some tissue-resident macrophages (e.g., found in
intestine, lung, mammary gland, skin, heart, osteoclasts). The tissue-resident
macrophages derived from monocytes have a limited half-life and no self-renewal [3],
[35].

2.1.2 Macrophages in Tissue
The mononuclear phagocyte cellular system can be considered the sum total of
responses due to mononuclear cells, such as macrophages. It is adaptable and contributes
to both, adaptive and innate immunity. All macrophages, including tissue specific and
bone marrow-derived, are a part of it. Tissue-specific macrophages can be identified via
morphology, histological staining, or labeling of phagocytic particles. A common marker
for macrophage differentiation if the F4/80 antigen which is associated with endothelial
and epithelial cells as well as distribution in organ interstitium and connective tissue [36],
[37].
6

Macrophages have specific functions in the tissues they are localized in. For
instance, stromal macrophages have been found to support erythropoiesis, spleen
macrophages support cell turnover and innate and adaptive immunity, lung macrophages
protect airways, peritoneal macrophages guard the abdominal serous cavity, and neural
macrophages support development. Macrophages affect growth and development of
many tissues. [38]

2.1.3 Macrophage Polarization
Macrophage polarization refers to the activation of certain sets of macrophage
genes and deactivation of others. Macrophages are very plastic cells with the ability to
have varying gene expression. They variation in expression is in response to many signals
such as debris, tissue trauma and infection. Activated macrophages are generally
categorized as M1 or M2 macrophages. M1 macrophages are inflammatory in phenotype
and has toll like receptors and interferon signaling. These are associated with
inflammatory response such as to bacterial invasion. M2 macrophages are associated
with fibrosis (i.e., extracellular matrix deposition) and tissue repair and regeneration.
They also play a role in TH2 immunity. [5], [25], [39], [40]
Macrophages are directly associated with the inflammatory response. Cellular
environments such and expression and cytokine presentation play a large role on
polarizing macrophages. Roles are varied in both resolving and non-resolving
inflammation. Resolving inflammation occurs in the normal healing process in which cells
are properly regulated and M1 macrophages turn into M2 macrophages, whereas non7

resolving inflammation has prolonged inflammation such as what occurs in chronic
inflammation. [5], [41]

2.1.4 Resolving Inflammation vs Non-resolving Inflammation
During resolving inflammation immune cells are recruited to the site of injury i to
return tissue to homeostatic conditions. Monocytes and neutrophils arrive from the
blood. Monocytes then differentiate into macrophages, which are then induced into an
M1 phenotype. These then release cytokines to help promote repair and regulate healing,
however this complex pathway is still not fully understood. When the debris and injury
components are cleared up the monocyte-derived macrophages (MDMs) then become
more fibrotic. Eventually most MDMs leave the site or die, while some convert properties
to become similar to resident tissue macrophages. [5], [42]
Non-resolving inflammation occur in diseases such as cancer, autoimmune
diseases, and chronic inflammation and wounds. Monocytes are chronically recruited to
the site of inflammation, increasing output of myeloid cells. [43], [44]

2.1.5 Macrophages in Inflammation
Macrophages play a major role in inflammation through their immunological
response to remove foreign substances and by rapidly producing cytokines to invoke the
inflammatory response. These cytokines have several functions; therefore, macrophages
play multiple roles in inflammatory response. Cytokines involved in the inflammatory
response include IL-1β, TNF-α, and IFN-γ, while those involved in the anti-inflammatory
response include IL4, IL-13, CCL-18, CCL-22, TGF-β and VEGF [45]–[47]. Macrophages also
8

release chemokines and antimicrobial peptides when activated. Although the
inflammatory process is aimed to be beneficial by removing foreign substances and dead
cells, it can also cause tissue destruction. When macrophages are exposed to IFN-γ,
cytokine production and the inflammatory response is greatly increased, often resulting
in an increase in tissue destruction. [48]–[50]
Macrophage expression of cytokines is a complex process and depends on
environmental ques such as exposure to pathogen associated molecular patterns
(PAMPs) or activation of the kinase-dependent signaling pathway. The kinase-dependent
signaling pathway responsible for macrophages activation and cytokine production
results in transcription of IFN-γ, NF-κB, CREB and AP-1. Macrophages respond to
pathogen-associated molecular patterns (PAMPs) such as lipopolysaccharides (LPS) by
producing tumor necrosis factor (TNF) [51]. TNF further promotes release of several other
inflammatory cytokines including interleukin 6 (IL-6), IL-12/23 and type 1 interferons.
Lineage specific receptors which can have differing responses to these cytokines are
uniquely represented in macrophages residing in specific tissue types. Macrophages are
adept at promoting inflammation in response to LPS due to pattern recognition receptor
toll-like receptor 4 (TLR4) and activation via lineage-specific transcription factors including
PU.1 and C/EBP [52], [53]. Other transcription factors associated with TLR signaling
include signal transducer and activator of transcription (STATs). STAT1, STAT2, STAT4, and
STAT5 induce inflammation while STAT3 and STAT6 induce transcription of antiinflammatory genes. TLR signaling is also mediated by microRNA (miRNA) which are small
strands of RNA (21-25 nucleotides in length) that act to suppress gene expression [51],
9

[54]–[56]. Dysregulation of macrophage miRNAs is seen in disease phenotypes such as
cystic fibrosis [57]. [58]
Inflammatory mediators modulate macrophage activity effectively turning off or
on inflammation. As such there is much research into inhibition and promotion of these
mediators either directly such as with gene silencing or indirectly by affecting another
molecule upstream in their pathway. Such mediators include TNF-α, IL-1β, IL-6 and IL-12.
TNF-α plays a central role in initiating the inflammatory cascade, and there has been some
success targeting TNF-α with antibodies to reduce inflammation [59]–[62]. IL1 α and β are
proinflammatory cytokines that affect many tissues and cell types and both signal through
IL1 receptor 1. IL-1β is important for homeostatic regulation of sleep, temperature and
digestion [63]. It has specifically been targeted due to its implication in pain, inflammation
and autoimmune diseases such as rheumatoid arthritis, osteoarthritis, multiple sclerosis
arthritis, Alzheimer’s disease, and inflammatory bowel disease [64]–[67]. Many drugs
target IL-1β or act as an antagonist against its receptors, however it is involved in
regulation of many cells and tissue and is released from macrophages as well as many
other cell types including mast cells and microglia, so treatments may cause adverse side
effects [66]. [58]
Other approaches to decrease inflammation work to generally reduce it (not just
one cytokine) such as with nonsteroidal anti-inflammatory drugs (NSAIDs), steroids such
as glucocorticoids, kinase inhibitors especially for janus activated kinases (JAKs), spleen
tyrosine kinase (SYK) and mitogen-activated protein kinases (MAPKs), and receptormediated inhibition to directly inhibit macrophage activation. NSAIDs inhibit
10

cyclooxygenase (COX) enzymes to reduce prostaglandin inflammation by inhibiting
eicosanoid production and has proven helpful for osteoarthritis and cancer [68]–[71].
Glucocorticoids are a group of corticosteroids involved in metabolism of proteins and
carbohydrates and is the most common treatment for many chronic inflammatory disease
including diseases such as asthma, cancer and COPD [72]. Glucocorticoids reduce several
inflammatory cytokines including IL-6, IL-12, TNF-α, and IL-1β [73]. Glucocorticoids can
reduce NF-κB and AP-1 activity, protein kinase C, MAPKs, and several downstream
inflammatory cytokines [73]–[75]. Glucocorticoids also increase anti-inflammatory
transforming growth factor beta (TGF-β) [76]. [58]

2.1.6 Macrophages in Inflammatory Disease
Macrophages play a key role in response to pathogens, immunity and maintaining
homeostasis during inflammation. As such they play an important role in managing
inflammatory disease. Inflammation is caused by either a biological disorder such as
inflammatory bowel disease (IBD), heart disease, stroke, cancer, diabetes, neurological
disease, respiratory disease or the body’s response to a foreign object or infection. These
inflammatory diseases account for approximately 70% of all deaths in the United States,
and 63% worldwide according to the CDC [77]. Inflammatory disease is caused by
excessive inflammation and macrophages which are responsible for ameliorating the
disorder are predominantly stuck in the M1 phenotype. [77]–[79]
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Recently there has been much interest in the development of therapeutics which
induce an M1 to M2 transition in macrophages [7], [78], [80], [81]. Types of tissue
engineering therapeutics include nanoparticle and patch loaded drugs. Wound patches
could be helpful especially for skin wounds and may be an ideal application of our study.
As inflammatory mediators, macrophages play an important role in healing normal
wounds and play a large role in chronic wounds. During normal wound healing, genetic,
epigenetic and molecular processes work together [82]. Macrophages direct
inflammation, tissue remodeling and repair, and the transition into the proliferative
phase of wound healing. However, during chronic wounds tissue is constantly destroyed.

2.2 Skin Wounds
The skin serves as a barrier which acts to protect against physical damage, chemical
damage, loss of fluid, thermoregulation, and to prevent infection[83]. Layers of the skin
include the epidermis, dermis, and subcutaneous tissue as shown in Figure 1 [84].
Damage can affect one to all layers of the skin and can cause serious issues even leading
to death. Wound healing is a complex process that can be disrupted by many conditions
such as age, sex, infection, smoking, obesity, diabetes, vascular disease, and malnutrition
[85], [86].

12

Figure 1. Skin Anatomy
From Andrews’ Diseases of the Skin: Clinical Dermatology (10th ed., p.1), by W.D. James, T.G.
Berger, and D.M. Elston, 2006, Philadelphia: Elsevier Saunders.

Wound healing is an integral homeostatic process necessary to maintain barrier
protection. It is a complex process involving many cells, notably macrophages and
fibroblasts. Other hematopoietic and non-hematopoietic cells are recruited including
neutrophils, natural killer cells, T cells, B cells, stem cells, epithelial cells and endothelial
cells [87]. Macrophages are present throughout the entire wound healing process;
however, they play the largest role during the inflammatory phase and proliferation
phase. Macrophages digest tissue and cellular debris, regulate inflammation, the process
conversion from inflammation to tissue deposition, and support cell proliferation [88],
[89]. Inappropriate regulation can lead to excessive inflammation or fibrosis.
Macrophages also promote fibroblast proliferation. Fibroblasts are important for tissue
13

deposition. They produce collagen, glycosaminoglycans, and help to regulate the process
by releasing growth factors and cytokines [90]. However efficient the wound healing
process is, it does not result in complete regeneration of the tissue and is considered a
reparative process.

A scar is left behind preventing complete recovery of skin

function.[91]

2.2.1 Wound Closure
Wound closure happens in one of three ways, primary, secondary, or delayed
primary, depending on the given situation (Figure 2).

Primary wound closure, also

known as primary intention, occurs when the wound is small and clean. It is often caused
by surgical incision or small clean cuts such as paper cuts. Most wounds heal by secondary
wound closure. Secondary wound closure, also known as secondary intention, are
rougher and require granulation tissue matrix to fill in the defect. It takes longer than
primary wound closure and creates more scar tissue. Delayed primary wound closure also
known as third intention wound healing is somewhat similar to both primary and
secondary wound healing. It occurs when a surgeon opens a wound, cleans it and leaves
it for a few days to ensure there is no infection before closing the wound back up to heal
via primary intention. This is performed for traumatic injuries when foreign bodies enter
the site such as in dog bites and lacerations.[92]

14

Figure 2. Wound Closure
From Schwartz’s Principles of Surgery 9th ed, by Brunicardi FC, Andersen DK, Billiar TR, Dunn
DL, Matthews JB, Pollock RE, 2009, McGraw-Hill.
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Skin wounds pose a significant problem affecting all people at some time or
another. There are many types of open skin wounds including abrasion, laceration,
incisions, punctures, avulsion and amputation. Wounds causing damage to the full
thickness of the skin including all three layers are the most dangerous, common examples
include burn wounds, ulcers and chronic wounds [93].

2.2.2 Types of Wounds
Wounds can be considered either as acute, chronic of complicated.
Acute Wounds
Acute wounds heal themselves normally within 30 days. They are wounds that
cannot be healed by primary intention. Acute wounds can occur due to a number or
reasons such as biopsies or traumatic injury. Acute wounds can have other injuries
associated with them (e.g., broken bone). Both exposed and internal wounds fall into this
category [94].
Chronic Wounds
These are wounds that become stalled in one or more phases of the wound
healing process, such as the inflammatory phase. Various factors may prolong these
stages such as hypoxia, necrosis, infection, and cytokine expression. Causes include
pressure, arterial insufficiency, venous insufficiency, burns, age, genetic components
and pressure. Continuous inflammation perpetuates a non-healing state. Even when
healed, the healed area is mechanically weak and prone to relapse [94].
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Complicate Wounds
Complicated wounds are a combination of chronic infection and tissue defect.
The cause is due to traumatic injury, such as from an accident or surgery. The wound is
contaminated and manifestation of infection depends on virulence, amount of
pathogen, blood supply and patient immune system [94].

2.2.3 Phases of Wound Repair
When skin is wounded it goes through four phases to repair the damage.
Phase I: Hemostasis
This phase is the first response to injury primarily to stop the flow of blood. This
step occurs within a few minutes of the initial injury. Upon damage host cells release
adenosine diphosphage prompting platelets to bind to collagen. Resident macrophages
help to regulate clotting [95]. Glycoproteins are released resulting in platelet aggregation.
Platelets and the coagulation cascade are activated. Platelets then release
vasoconstrictive chemicals locally. Platelets are also responsible for formation of a fibrin
clot and initiation of several growth factors including transforming growth factor (TGF),
platelet derived growth factor (PDGF), fibroblast growth factor (FGF) and vascular
endothelial growth factor (VEGF). Growth factors then recruit neutrophils, monocytes
and fibroblast and stimulate epithelial cells[93], [96].

17

Phase II: Inflammation
This stage generally lasts up to 4 days. Blood vessels become leaky allowing plasma
and neutrophils to enter the site of inflammation. Neutrophils are considered the first line
of immunological defense and help to phagocytose and trap infection/debris.
Inflammatory cells including monocytes, macrophages, neutrophils and T lymphocytes
migrate to the site and remove bacteria, dead cells, damaged tissue and foreign materials
via phagocytosis. Monocytes migrate to the site from the blood stream and develop into
monocyte derived macrophages (MDMs). Neutrophils have a very short half-life dying
quickly which and worsen inflammation, however normally macrophages can help clear
their remains. These cells also release more cytokines and growth factors to modulate the
healing process and migration/activation of fibroblasts. The site of injury becomes warm
and swells due to the influx of cells. Necrotic tissue, extracellular matrix and fibrin is
broken down via matrix MMPs to set the stage for tissue deposition. MMPs are secreted
by neutrophils, macrophages, epithelial cells and fibroblasts in response to inflammatory
cytokines including TNF-α, IL-1, and IL-6 [96].
Chronic wounds and many inflammatory diseases progression of wound healing is
stalled at this phase. This may be caused by increased bacterial burden or some
underlying disease. [97]
Phase III: Proliferation
In acute wounds proliferation starts at around day 4 and lasts until around day 21.
Macrophages, lymphocytes, angiocytes, neurocytes, fibroblasts and keratinocytes work
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to deposit extracellular matrix and re-establish skin function. There is angiogenesis,
collagen deposition, wound contraction and epithelialization. Macrophages help to
regulate this phase by communing with surrounding cells via cytokines. [96]
Phase IV: Remodeling
The remodeling phase constitutes the realignment of collagen to improve the
mechanical strength of the tissue. This process can take up to 2 years to finish. Fibroblasts
are the main cells involved. Overall cell density decreases in the area while strength is
increased. [96]

2.2.4 Chronic Wounds
Chronic wounds include diabetic ulcers, venous leg ulcers, and pressure ulcers and
they are defined by ulceration lasting greater than 2 weeks. Wound healing becomes
more difficult with age, and chronic wounds become more prevalent in the elderly
population [98], [99]. Biofilm-infected cutaneous wounds extend the duration of the
wound making treatment more complicated [100]. Chronic wounds become suspended
during the inflammatory phase and are commonly accompanied by infection, continued
neutrophil accumulation, disordered macrophage polarized in M1 phenotype, disordered
lymphocyte function, high levels of proteases, and dysregulation of cytokines/growth
factors with inflammatory cytokines being overexpressed [101].
Chronic wounds can be characterized by dysfunctional cytokine expression and
growth factor activity [43], [102]. Increased inflammation leads to chronic expression of
M1 type macrophages causing unique expression of growth factors and sustained
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protease activity such as matrix metalloproteinase 2, 9 and 14 [103]. During the prolonged
inflammation phase there are elevated levels of inflammatory cytokines including IL-1α,
IL-1β, IL-6 and TNF-α, as well as a large presence of neutrophils [104].
In wounds there is also elevated levels of ROS due to continued presence of
neutrophils which release them [105]. Macrophages are able to clear neutrophils during
normal wound healing, however since they are stuck in an M1 phenotype they continue
to recruit more neutrophils to the wound site further exacerbating the condition [106].
The presence of superoxide contributes to inflammation and tissue destruction [107]–
[109].

2.2.4.1 Current Therapies for Chronic Wound Treatment
Treating chronic wounds is a difficult task. A thorough assessment of the wound
and patient condition must be described first [110]. Infection poses a particular threat
due to the ability of biofilms to evade traditional treatment, they are generally
approached with antibiotics and/or tissue debridement [111]. Infection must be treated
aggressively. Physicians follow the TIME protocol for wound healing, Tissue assessment,
Infection control, Moisture management, Edge of wound management. After
management and infection control the wound debridement is an important step to
remove the current inflammatory environment and return the wound to more of an acute
wound setting. Scalpel, ultrasound and/or enzymes can be used for debridement. The
wound is then covered with some sort of wound dressing. Pressure to the wound must
be carefully managed especially for pressure associated wounds. Offloading pressure for
pressure ulcer healing away from the wound is important, therefore devices such as
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braces, casts or specialty shoes may be used in addition to the wound patch. Venous leg
ulcers oppositely need compression to help control interstitial fluid build-up. If the wound
is not healing, then amputation may be considered [85], [112].
There are several topical therapies that promote wound repair, however their
therapeutic effect is limited. Some topical agents include antibiotics, silver, cadexomer
iodine, honey, collagenase, saline and hydrogel loaded drugs [113]–[115]. Many dressings
are used, such as cotton gauze, hydrocolloid dressings, hydrogel dressings, acrylic
dressings, semipermeable film dressings, alginate dressings, hydrofiber dressings, semipermeable foam dressings, bioactive wound dressings and tissue based products [116]–
[118]. If the wound is serious enough, advanced therapies can be considered, such as skin
graft or amputation. New therapies have been recently developed which focus on tissue
engineering technologies. These include growth factor treatment, acellular skin grafts,
skin substitutes and cellular therapies such as with fibroblasts, keratinocytes and/or stem
cells. Therapies have also been designed to treat the oxidative stress and inflammatory
environment of wounds such as the antioxidant drug catechin ECG which inhibits MMP-2
and MMP-9, or activated protein C (APC) which binds to receptor endothelial protein C
receptor (EPCR) to inhibit NFκB and reduce inflammation [104]. [85], [112]

2.3 Electrospinning
Electrospinning is the process by which electrostatic force is used to pull polymers
from a liquid solution in the form of fibers. The solution evaporates and only the polymer
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is left on the collector. This is an efficient method for producing fibers of nanometer
diameter. Electrospinning has been developed by scientist, industrial professionals and
entrepreneurs collectively since the early 1900s [119].

2.3.1 Applications of Electrospinning
Electrospinning can be used for many applications in industry and biomedicine, due to its
capacity to produce nanofibers. Other processes that can be used to produced nanosized
fibers include drawing, which has been discontinued due to limited control of fiber
dimension and scalability, self-assembly which is very complex and does not have good
scalability or control of nanofiber size/uniformity, phase separation which is limited to
specific polymers however again it has poor scalability or control over fiber dimension,
and template synthesis which allows for control over fiber dimension but also does not
have good scalability. Electrospinning has been used for applications in filters, smart
textiles and protective clothing, battery and capacitors, sensors, catalysts, drug delivery,
tissue engineering, wound dressing, cosmetics and composite reinforcements, the top
three being composite reinforcements, filters and tissue engineering [120].
Electrospinning offers a simple and cost-effective process to provide nanofibers which is
both scalable and offers control over nanofiber dimension. [121]
In industry the small fibers form a porous structure, which can be used for
filtration, composite materials or as a membrane. Electrospinning is used to create
composite fibers allowing multiple polymers to be easily and uniformly combined.
Composites allow for altering uses and material properties [122]–[124]. Morphology,
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diameter and arrangement of nanofibers can be controlled to suit the application.
Electrospinning is commonly used to produce fibers used for tissue engineering scaffolds
such as wound patches and scaffolds for tissue regeneration [125], [126]. Polymer
properties must be optimized for the nanofiber application such as porosity,
biocompatibility and tensile strength. Electrospinning of tissue engineered scaffolds can
incorporate molecules, proteins and even live cells [127]–[130]. Fibers can also be aligned
for applications such as nerve-tissue engineering [131]–[134]. Nanofiber scaffolds can be
modified to optimal pore size for drug loading in the scaffold. Drugs can either be
electrospun with the polymers or loaded afterwards. [121]
There are several polymer and solvent combinations that can be used for
electrospinning. A few common polymers include PLA, PCL, PLGA, PEG, PEO, and collagen.
A few common solvents include Water, DMF, DCM, Chloroform, ethanol, and THF.
Proteins like bovine serum albumin (BSA), DNA, RNA and growth factors can be
incorporated into the polymer solutions and electrospun into the fibers as well. Different
drugs can be loaded into electrospun scaffolds, including ibuprofen, ketoprofen, mefoxin,
doxorubicin hydrochloride, fenbufen, paclitaxel, and dichloroacetate [135]–[140], [141],
[142].

2.3.2 Process
In electrospinning an electric field polarizes the solvent and causes electrostatic repulsion
from the needle and attraction of the oppositely charged plate. There are many setups,
one of the most common involving a horizontal plate and syringe parallel to the ground.
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This setup will be discussed and is depicted in Figure 3. This setup consists of a single
horizontal plate and syringe placed parallel to the ground. There are many other methods
of performing electrospinning. Other common versions include a rotating drum to align
nanofibers, and also a vertical plate set up in which gravity has more of an effect of the
spinning and Taylor cone formation [143]–[145].

Figure 3. Electrospinning Process

Polymers are first dissolved in the solvent of choice. The solvent can affect the
properties of the nanofibers so appropriate solvent and polymers must be chosen. Drugs
or other materials can be added at this time to the solution. The solution is then loaded
into a syringe and a blunt needle is attached. Needle diameter is one of the factors that
can be adjusted to improve nanofiber diameter. Environmental conditions can be
adjusted based on solution components (e.g., light sensitivity or temperature). The
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distance between the collector plate and the needle is one of the parameters affecting
the nanofiber diameter. The flow rate setting on the syringe pump also affects the
nanofiber diameter. A faster flow often yields a smaller diameter. The positive electrode
is connected to the needle tip and the negative to the collector plate. The collector plate
should be made of a conductive material. When everything is set, the syringe pump and
power supply can be turned on. A small Taylor cone should appear, and a line should be
visible coming from it and going towards the collector plate. The power supply voltage
can be modified to adjust material properties. Results depend on the polymers and
solvent being used. As weight percentage of the polymer increases in solution the critical
voltage for fiber formation also increases. Electrospun nanofibers are often characterized
by SEM and FTIR to confirm nanofiber morphology, diameter and composition. If beading
occurs during the fiber formation, the flow rate should be increased to make sure the
needle and collector are making continuous contact. If fibers form ribbons, a higher
polymer concentration or more volatile solvent should be used. To make the nanofibers
more porous, a more rapidly evaporating solvent should be used, and for smaller pores a
less rapidly evaporating solvent can be used [146]–[149].

2.4 Polymer Comparison
The intention behind this project is to develop a wound patch for healing chronic
wounds. Therefore, we decided to work on converting M1 macrophages into M2
macrophages. To this end several polymers were initially compared in Table 1. Pullulan
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was shown to be relatively inexpensive, with good mechanical strength, easily modifiable,
capable of quenching reactive oxygen species (ROS) and promoting neovascularization.
Reducing ROS should help reduce inflammation and neovascularization is an important
step in wound healing. Compared to other polymers, this seemed the better for wound
healing. Gelatin was added to improve cellular adhesion and due to its ability to support
wound healing by attracting fibroblasts and macrophages. Ethylene Glycol Diglycidyl
Ether was chosen as the chemical crosslinker between the polymeric fibers due to its
biocompatibility and proven ability to crosslink both polymers [150], [151], [28], [29],
[152], [153].

Pullulan [28], [154]–[158]; Gelatin [155], [159]–[161]; Chitosan [160], [162]–[164]; Elastin[165]; ELP
[161], [166]; Fibrin [159], [167]; Alginate [168], [169]; HA [170]–[172]; PEG [173]–[175]
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Criteria
Source
Degradation

Potential
Crosslinker

Biocompatibility

Source

Composition

Alterability

Additional
Features

Pullulan
[28], [154][158]
Aureobasidium
pullulans
50% in 20 min
EGDE,
Cysteamine,
trisodium
trimetaphospha
te, (1,4butanediol?)
Good, reduces
ROS, promotes
neovascularizat
ion
polysaccharide
Composed of α
1,6 linked
maltotriose
units (G3),
each with 2 α
1,4 glycosydic
bonds
Good, 9 easily
modified OH
bonds
high water
absorption,
good mech.
properties

Connective Tissue

Gelatin
[155], [159]-[161]

Chitosan
[160], [162]-[164]

Elastin
[165]

Natural- ex
tropoelastin

ELP
[161],[166]

Composed of simple
amino acids. Made by
linking tropoelastin
protein molecules

Protein

Natural- ex. bovine
neck tendon
Doesn’t degrade
quickly
Glutaraldehyde

β-(1→4)-linked Dglucosamine and Nacetyl-D-glucosamine.
Basic. Soluble in acidic
pH

Altering peptide
repeats and amino
acid
Nonimmunogenic,
good for drug
delivery

Peptide of
tropoelastin
Composed of
sequence [VPGXG]n
where x represents a
common amino acid
except proline.

Natural- from shrimp
shells
5-15% after 1 week in
vivo
photo crosslinking,
Hyaluronic Acid

25% after 1 day, 330% after 1 day
EGDE,
Glutaraldehyde, photo
crosslinking, PEG,
1,4-butanediol

Good

Protein, 3 α helical
peptide chains to form
a triple helix. Hi
content of
hydroxylated amino
acids

Primary amines. High
charge density.

Polysaccharide

Good, OH bonds

Forms films,
antimicrobial, anti
inflammatory

Good. Promotes
clotting and ECM
formation. Attracts
fibroblasts and
macrophages
Protein

Good cellular
attachment
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Criteria
Source
Degradation

Potential
Crosslinker

2days-1month

Fibrin
[159], [167]
Blood Plasma

ADA, 1-ethyl-(3dimethylaminopropyl)
carbadiimide
hydrochloride

Biodegradable

Alginate
[168], [169]
Brown Algae

Good, facilitates structure
during early wound
healing, promotes
keratinocyte activity

Photo-crosslinking

66% in 30min, sHA1-AC
took 24-48 hours

HA
[170]-[172]
Extracellular Matrix

Biodegradable synthetic

Good

Photo-crosslinking

Varys depending on
composition

PEG
[173]-[175]
Synthetic

Thrombin, calcium
chloride

Good

Synthetic/natural hybrid

Polyether with common
structure. Available in
multiple geometries

Synthetic/natural hybrid

Highly alterable

Protein

Binding with benzyl
alcohol makes HA more
alterable

Nonionic

Anionic polysaccharide

Polysaccharide common
to most species, weakens
ECM and permits cell
migration, anionic

Fibrinogen and thrombin

Gels at skin temperature,
pro inflammatory, high
levels of endotoxins,
component of biofilms of
P. aeruginosa

Non-sulfated
glycosaminoglycan
(GAG)

Prevents wound
contraction[15]

Good, supports
hemostasis, inflammatory
Biocompatibility cell recruitment,
angiogenesis
Source
Chemical
Composition

Alterability

Additional
Features
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Table 1. Polymer Comparison.
Polymers compared are: pullulan, gelatin, chitosan, elastin, elastin like peptide (ELP),
fibrin, alginate, hyaluronic Acid (HA), and poly ethylene glycol (PEG). Properties
examined were: degradation, crosslinker, biocompatibility, source, chemical
composition, alterability and any additional feature that promote biomedical
applications

2.5 Cross-linking
Cross-linking is the process of chemically bonding a polymer or multiple polymers
together and is usually done to increase the mechanical properties of the material.
Electrospun nanofibers used in medical application are often crosslinked to prevent
immediate degradation in moist environments [176]–[179]. Stability of the crosslinked
product is dependent on the type of polymer, type of cross-linking agent, concentrations
and environmental conditions, such as temperature, play a large role in the chemical
reaction which produce the cure effect on the final product [180]. Stability of the polymer
post-crosslinking depends on the degree of crosslinking, the stability of the crosslinker
and of the polymer/polymers used, and environmental conditions (i.e., pH, temperature,
mechanical trauma, etc.). Crosslinkers generally have two or more reactive groups and
react with functional groups such as hydroxyl, carboxyl, amine and sulfhydryl. Crosslinkers
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can be specific or less so in the case of photoreactive crosslinking. Crosslinking is used for
scaffold strengthening and material immobilization (e.g., drugs or biomolecules) [181].
Common crosslinkers include those containing functional groups such as
maleimide, sulfhydryl and succinimidyl esters. Sulfosuccinimidyl esters are water-soluble
crosslinkers and are useful for crosslinking when organic solvents should not be used. The
chemical structure of the polymer is altered due to crosslinking. This can change the
polymers functional properties. Crosslinkers can form polymers from monomers,
covalent bonds between polymers or ionic bonds between polymers. There are also
cleavable crosslinkers like sulfoxides. Energy can be added to stimulate the reaction via
heat or pressure. High-energy ionizing radiation such as from gamma radiation, x-ray, or
electron beam can also be used to crosslink material. [182]
Crosslinkers can be used to create polymers from monomers, to connect multiple
polymers, proteins, or larger structures. There are physical crosslinkers and chemical
crosslinkers. Physical crosslinking occurs by ionic interaction, crystallization, protein
interaction, hydrogen bonds, steric complex formation, or hydrophobic interactions.
Chemical crosslinkers synthesize polymer growth or polymer bonding. Chemical
crosslinkers include homobifunctional crosslinkers and heterobifunctional crosslinkers.
Homobifunctional crosslinkers have identical reactive groups and are used to affix certain
functional groups they react with. Heterobifunctional crosslinkers have different reactive
groups allowing conjugation of molecules with dissimilar reactive groups. Example
crosslinkers include disuccinimidyl suberate (DSS), ethylene glycol diglycidyl ether (EGDE),
glyoxal, silane, glutaraldehyde, and ethylene glycol dimethacrylate [183]–[190]. These
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crosslinkers can be combined with polymers such as poly(vinyl alcohol) (PVA),
poly(ethylene glycol), proteins, gelatin, chitosan, cellulose, polyacrylamide, and alginate
[191]–[197]. Hydrogels are an example of crosslinked polymers that are often used in the
biomedical industry. Electrospun fibers can also be used as hydrogels for wound dressing
and other purposes [198]–[200]. Polymers and crosslinkers can be used in a variety of
industries such as packaging, adhesives, textiles, food, drug delivery and tissue
engineering. [182]
Hydrogels are macromolecule gels constructed from chemically crosslinked
polymer chains. They are synthesized from monomer crosslinking or by crosslinking of a
polymer (e.g., crosslinking of electrospun nanofibers). Hydrogels can provide ideal
conditions for drug delivery and as a scaffold for tissue engineering [201]–[206]. [182]

2.5.1 Ethelene Glycol Diglycidyl Ether (EGDE)
Ethylene Glycol Diglycidyl ether (EGDE) is a common crosslinking compound and
has been used for crosslinking polysaccharides, proteins and organic molecules such as
chitosan and gelatin [207]–[210]. Crosslinking with EGDE improves water resistance and
mechanical properties of its target. EGDE has been effective for crosslinking gelatin
pullulan, chitosan, lignin, DNA and PVA as reported by several authors [150], [211]–[216].
EGDE has been shown to have better biocompatibility than the common crosslinker
glutaraldehyde [217]. EGDE contains two highly reactive epoxide functional groups at
either end of the molecule. The three-member ring is a cyclical ether that is very reactive
due to strained covalent bonds. This allows EGDE to bind with hydroxyl, carboxylic and
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amine functional groups (Figure 4) [218]. Temperature and pH may be adjusted to
improve crosslinking [215]. EGDE is able to react at a wide range of pHs, however citric
acid is commonly used to catalyze the reaction [150]. [151], [218]

Figure 4: Crosslinking Reaction of EGDE with Hydroxyl, Amine and Carboxyl Groups
(Poursamar et al, 2016) [220]

2.6 Pullulan
Pullulan is a polymeric exopolysaccharide commonly extracted from the yeast like
fungus Aureobasidium pullulans. It has been gaining traction for use in tissue engineering
due to its high biocompatibility and tissue regenerative properties. Pullulan is nonhygroscopic, dissolves readily in water and is an FDA approved food additive that is slow
digesting and low in calories making it ideal for food preservation. Due to its lack of
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functional groups promoting cell binding, it should form a copolymer with proteins
providing such binding motifs, such as gelatin [28], [29], [219]. [152]

2.6.1 Properties of Pullulan
Pullulan is a linear, unbranching, amphiphilic molecule composed of 9 hydroxyl
groups making it easily modifiable and crosslinkable such as with EGDE. It is composed of
repeating α (1-4) maltotriosyl units (3-D-glucopyranosyl) with adjoining α(1-6)bonds
[220]. Pullulan can reduce reactive oxygen species which can improve the inflammatory
environment in wounds [15]. It has good mechanical properties, hydrophilic,
hemocompatible and has good swelling ability. [155]

2.6.2 Pullulan Production
Pullulan is industrially produced by fermenting liquified starch from a source such
as sucrose, glucose, soy bean oil, beet molasses and/or coconut byproduct with A.
pullulans [221]–[223]. Besides being produced by Aureobasidium pullulans , other yeast
and fungi also produce pullulan including Cytaria darwinii, Teloschistes flavicans,
Rhodotorula bacarum and Cryphonectria parasitica [224]–[226], [26].

2.6.3 Pullulan Application
Pullulan has proven to be an ideal polymer for applications in vascular tissue
engineering, cartilage repair, bone tissue engineering and wound healing [227]–[231]. It
is modifiable to form carboxymethyl pullulan and sulfated pullulan [232], [233]. Pullulan
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has been shown to improve osteoconductivity and provide mechanical stability for bone
and tooth repair [230]. Pullulan is an ideal polymer for wound healing due to its ability to
protect the wound from bacterial infection, its modifiability, and ability to maintain a
moist environment and prevent fluid loss [157], [234]–[236]. Pullulan has been used for
drug delivery and antibiotics can be loaded into pullulan without loss in bioactivity [237]–
[239]. Pullulan can be loaded with many cell types including mesenchymal stem cells,
macrophages, smooth muscle cells, and human endothelial cells [156], [227], [240].
Pullulan is shown to be effective to improve wound healing by including a copolymer such
as gelatin and/or by incorporating of mesenchymal stem cells [154], [156].

2.7 Gelatin
Gelatin is a biopolymer derived from the hydrolysis of the protein collagen. Both
collagen and gelatin are commonly used in tissue engineering. There are benefits to both.
Both have great biocompatibility, gelatin is inexpensive and easier to work with however
it has worst mechanical properties than collagen. Gelatin is commonly used in foods,
cosmetics, pharmaceuticals and for biomedical applications. It is especially well known
for its good cellular adhesion which is why it is often used as a copolymer for wound
healing applications [241].

2.7.1 Properties of Gelatin
Gelatin is a polypeptide containing 18 amino acids with large amounts of glycine,
proline, alanine and hydroxyproline. Gelatin is water soluble however it requires initial
34

heating to at least 35oC. Alkali processed gelatin has predominantly alanine while acid
processed gelatin is predominantly glycine. Gelatin structure is linear and characterized
by hydroxyl groups, carboxylic groups and amino groups. Some properties such as
peptide chain size and organization of bonds can be altered by the manufacturing process.
[242]

2.7.2 Gelatin Production
Gelatin is derived from skin and connective tissue. Commercially, gelatin is made
from cattle bones, animal skins, and fish skin [243]. Depending on the source, gelatin is
extracted by alkaline pretreatment or acid pretreatment resulting in gelatin with different
properties. These processes affect the isoelectric point, pH and other properties. Gelatin
type A (GA) which is acid pretreated has an isoelectric point of 8-9 and is positively
charged at neutral pH, and gelatin type B which is alkaline pretreated has an isoelectric
point of 4.8-5.4 and is negatively charged at neutral pH [244]. We used Gelatin Type A for
our experiments.

2.7.3 Gelatin Application
Gelatin is use in food due primarily to its gelling and thickening properties and is
used as a stabilizer in yogurt, and thickener in jam [245]. It is commonly used in tissue
engineering for application in drug delivery, wound healing and tissue regeneration [153],
[246], [247]. It is being used as a drug carrier of anticancer drugs such as curcumin,
paclitaxel, and doxorubicin (DOX), it has been used in polymer composites to improve
bone and skin regeneration, and it has been shown to act as an ideal wound healing
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scaffold component for hydrogels and has been used with other cell types such as
mesenchymal stem cells and fibroblasts in biomimetic scaffolds to facilitate healing [27],
[248]–[258].

2.8 Retinoic Acid in Wound Healing
Retinoic acid (RA) is a metabolite of vitamin A, and the most biologically active
intermediate in the retinol metabolic pathway [259]. It can be presented in multiple
isoforms such as the 13-cic-RA isoform, however, the all-trans isoform is the most
common in tissue and will be the focus here. RA is produced in vivo as a signaling molecule
for embryonic development and is known to play a role in axial patterning, neurogenesis,
limb and organ development, and lymphoid development [260]. It is not entirely sure
whether RA can be delivered between cells or that its’ production relies on stimulation
through other pathways. RA transcriptionally regulates gene expression by binding to
retinoid receptors such as RAR and RXR which are common in most cells. The effect of
activating retinoid receptors differ depending on the cell type [261], [262].
In stem cells, when RA is produced it is transported via CRABP2 to the nucleus. In
the nucleus RA binds to an RAR receptor. RAR then binds to an RXR receptor forming a
heterodimer which binds to DNA and activates transcription. Many genes are both
directly and indirectly regulated as a result. RAR and RXR need to be phosphorylated to
actively bind and react to RA. Co-activators and co-repressors can bind to the RAR/RXR
heterodimer to modulate this response [263].
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RA has been shown to decrease inflammation and regulate macrophages and
mesenchymal stem cells and to promote wound healing. RA is used therapeutically to
reduce injury and fibrosis in acute kidney injury, with studies showing M1 inflammatory
macrophages become alternatively activated to M2 phenotype [264]. Pourjafar, et al.,
showed that pretreating MSCs with all-trans RA improves MSC viability and activity, and
enhances overall proliferation and angiogenesis in a rat incision wound model [13]. In
another study Abdelhamid, et al., showed that after exposing MSCs and peripheral blood
mononuclear cells (PBMCs) to lipopolysaccharide (LPS) which stimulates an inflammation,
treatment with RA improved viability and reduced the inflammatory response [265]. RA
has also been shown to effectively convert M1 macrophages into M2 phenotype [266].
Lin, et al., showed that RA can stimulate M1 to M2 conversion, reduce inflammation and
significantly improve wound healing; furthermore they found that M2 macrophages
treated with RA causes activation of Arg1 which is a crucial gene for wound healing [267].
Overall RA decreases inflammation, improve angiogenesis, convert M1 macrophages to
M2 macrophages and improve wound healing making it a novel therapeutic for
inflammatory diseases such as chronic wounds.

2.9 Mesenchymal Stem Cells in Wound Healing
Mesenchymal stem cells (MSCs) have the ability to renew themselves and to
differentiate into many cell types including adipocytes, chondrocytes, osteoblasts,
myoblasts, fibroblasts and chondroblasts [268]. MSCs can be found in multiple locations
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in the human body including bone marrow, adipose tissue, synovial tissue, and lung
tissue. They are often isolated from bone marrow (bone marrow derived mesenchymal
stem cells = BMSCs) or adipose tissue (adipose derived mesenchymal stem cells =
ADMSCs) for research purposes. Adipose derived stem cells are particularly useful due to
their ease of harvest and accessibility. MSCs help to maintain homeostasis and play a role
in wound healing. MSC treatment has the potential for regeneration due to its ability for
reverse remodeling, cell regulation and to differentiate into important cells at the wound
site. They can be identified by the surface markers CD73, CD90 and CD105. MSCs have
been shown to suppress inflammation from neutrophils, macrophages, dendritic cells,
natural killer cells, mast cells and eosinophils [269].
In cutaneous wounds MSCs use paracrine signaling to increase angiogenesis, regulate
inflammation and ECM, and enhance epithelialization and wound closure [270]. MSCs can
signal fibroblast and keratinocytes to migrate to the wound site [271]. They are also able
to inhibit the expression of MMPs which degrade tissue, thereby paving the way for
extracellular matrix deposition [23], [272]. Many studies have shown that MSCs are able
to improve chronic inflammatory disease and accelerate wound closure of chronic
wounds [16], [28], [273]–[278]. Rustad, et al., showed that pullulan and collagen
hydrogels loaded with MSCs induce MSCs to secrete angiogenic cytokines, promote
pluripotency and to promote stemness factors Oct4, Sox2 and Klf4 [154]. Wound
microenvironments can be harsh due to reactive oxygen species, inflammatory cytokines
and cytotoxic mediators. Kosaraju, et al., showed that ADMSCs seeded on pullulancollagen hydrogel enhances survival of ADMSCs in the wound environment and promote
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recruitment of circulating BMSCs [156]. Chen, et al., found that pullulan/collagen + MSC
hydrogels could inhibit M1 macrophage expression, promote secretion of TFG-β1 and
bFGF (known to regulate keratinocytes, fibroblasts and endothelial cells), and improved
wound closure [279]. In conclusion, MSCs can improve healing and regeneration in
chronic inflammatory diseases such as chronic wounds. In chronic wounds, MSCs,
pullulan, collagen/gelatin and RA can further improve wound healing via increased
angiogenesis, increased MSC stemness, decreased ROS, decreased MMPs and conversion
of macrophages from M1 to M2 anti-inflammatory phenotype.
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CHAPTER III
Materials and Methods

3

3.1 Electrospinning
The materials used for electrospinning were Concentrations of 200,000MW pullulan
(Hayashibara Laboratories, Okayama, Japan) and gelatin Type A gelatin from porcine skin
(Electron Microscopy Sciences, Hatfield, PA). The polymers were first dissolved in water
at 20wt%. Polymer concentrations electrospun were 100% pullulan, 75% pullulan/ 25%
gelatin, and 50% pullulan/ 50% gelatin. Solutions were heated to 50OC and magnetically
stirred for 30min to make the polymers go into solution. The solution was then sonicated
for 30min to get rid of bubbles. The polymer solutions were then loaded into 10mL BD
Falcon syringes with an attached 22-gague needle attached. The sample was then loaded
onto a syringe pump. The electrospinning process was carried out at 50oC by using a heat
gun to maintain liquid phase of the solution. The device setup consisted of a syringe
pump, a high voltage power supply (Information Unlimited, Inc.), and a collector plate
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covered with non-stick aluminum foil. Pullulan/gelatin composite solutions were loaded
in 10mL syringes and placed horizontally. The solution was expunged through a 22-gague
blunt-end needle and fibers were collected. The high voltage power supply was set to
37kV, the flow rate was set to 55μL/min (3ml/hr), and the distance between syringe
needle and collector plate was set to 18cm. The scaffolds were stored at 4oC in a vacuum
desiccator until analysis or crosslinking could be performed.

Figure 5. Pullulan/Gelatin Electrospinning Setup

3.2 Crosslinking
Crosslinking solutions were prepared at different ratios of EGDE to absolute ethanol. Both
pullulan and gelatin are known to be crosslinked by EGDE. Ratios tested were 1:100, 1:50
and 1:70 with the addition of 0.05M citric acid. Pullulan/gelatin nanofibers were
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immersed in crosslinking solution for 24h to crosslink. Crosslinked nanofibers were dried
at 50oC for 24h. This is a modified protocol based on a method described by Li, et al., to
crosslink gelatin [150].

3.3 Scaffold Loading
After crosslinking with EGDE, nanofiber scaffolds were loaded with RA. Nanofiber
scaffolds were first rinsed with PBS to remove any residue from EGDE crosslinker and then
sterilized with UV for 1h prior to loading to prevent contamination. RA was diluting in
EtOH, syringe filtered, and added to the sterilized scaffold, then dried. The amount or RA
added was 5μg or 10μg per 10μg scaffold (this is equivalent to 5mg/mL or 10mg/mL RA
in cell culture media respectively). Passage 4 ADMSCs were also loaded onto the scaffold.
ADMSCs were incubated with the sterilized scaffold for 3 min. If both RA and ADMSCs
were added to the same scaffold, RA was added first, dired, then the ADMSCs were
added.

3.4 Cell Culture
Human Monocytic THP-1 cells (ATCC® TIB-202™, Manassas, VA) were maintained at
Wright State University in RPMI culture medium (RPMI 1640, Life Technology, Grand
Island, NY) containing 10 % heat inactivated FBS (GE Hyclone, Marlborough, MA). THP-1
cells were differentiated into macrophages by incubating 24h with 200nM PMA (Cayman
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Chemicals, Ann Arbor, MI) and supplemented with 30ng/mL GMCSF (GenScript,
Piscataway, NJ) for macrophage growth. Using PMA is a commonly used method to
differentiate THP1 monocytic type cells into macrophages [280]–[283], [284, p.], [285, p.
1]. Macrophages were polarized to M1 macrophages by incubation with 100ng/mL LPS
(eBioscience, San Diego, CA) and 100ng/ml IFN-γ (Invitrogen, Rockford, IL) and incubated
at 37oC, 5% CO2 for 24h. Adult non-diabetic ADMSCs from Lonza were cultured to passage
4 in MSC basal medium (ScienCell, Carlsbad, CA). In co-culture experiments, THP-1 cells
were first differentiated in 24 well plates. After polarization, cells were washed and
resuspended in 1mL 10 % FBS with RPMI. ADMSCs were cultured from passage 3 until
confluent. They were then split and concentrated to 1 million cells per 10μL. 10μL of
ADMSCs were then added to the scaffold. They were incubated on the sterile electrospun
scaffold for 3 minutes, then loaded into transwell inserts (Corning, New York, NY).

3.5 Reagents
200nM PMA was used for macrophage differentiation. Macrophages were differentiated
in RPMI, FBS and GMCSF. Macrophages were differentiated for 24h then macrophages
were polarized. IFN-γ was used at a concentration of 100ηg/ml and LPS was used at a
concentration of 100ηg/ml for macrophage polarization to M1 type macrophages.
Macrophages were polarized to M1 phenotype for 24 hours then cells were washed and
treated. Treatments include RA and PGG. RA (Sigma Aldrich, Saint Louis, MO) was
dissolved in DMSO at 50mg/mL. Treatment of RA in culture was at 5μg/mL and 10μg/mL.
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3.6 Scanning Electron Microscopy (SEM)
SEM images of nanofiber scaffold were obtained using a Phenom Pro scanning electron
microscope. Electrospun nanofibers were sputter coated with 10nm of iridium. Scaffolds
concentrations imaged were 100% pullulan, 75% pullulan/ 25% gelatin, and 50% pullulan/
50% gelatin. Scaffolds were imaged with and without crosslinking with EGDE. Images are
representative of the average. Nanofiber diameters were measured using ImageJ
software. Diameter averages were compared statistically using JMP software. 3 images
were taken for each sample with 20 nanofiber diameters measured for each image.

3.7 Fourier-Transform Infrared Spectroscopy (FTIR)
Scaffold compositions were determined by loading onto an attenuated total reflectance
(ATR) attachment and using a Thermo Scientific Nicolet iS 50 FTIR (Thermo Fisher,
Waltham, MA). Scaffolds were tested with and without RA. Data was plotted in Excel.

3.8 Scaffold Degradation and Drug Release
For degradation the scaffold was crosslinked at either 1:70 or 1:50 EGDE in EtOH. After
crosslinking in EGDE RA dissolved in EtOH was added at either 5μg or 10μg and then
allowed to dry. The scaffold was incubated with 1mL Ringers solution in 37oC incubator
with shaking at 100rpm. Samples for each concentration was measured in quadruplicate.
44

The same sample was used consistently for both drug release and degradation. Ringers
solution was collected and analyzed for RA using a spectrophotometer at 316nm. Time
points for drug release collection was 1h, 4h, 8h, 24h, 72h, 168h. Time points for scaffold
degradation was 1day, 3days, 7days, 14 days. For time points that coincide between drug
release and degradation, Ringers solution was collected then scaffold was dried at 50oC
for 24h and the weight of the contents measured. 1mL of fresh Ringers solution was then
added and incubation was resumed. RA concentration was measure using a
spectrophotometer at 316nm wavelength. Statistics for RA release and scaffold
degradation were measured using two-way ANOVA.

3.9 Live/Dead Imaging
An Invitrogen ethidium/calcein kit (Invitrogen, Rockford, IL) was used to stain for live and
dead cells. Ethidium penetrates damaged cell while Calcein is retained only by living cells.
Live and dead cells were imaged using a Leica fluorescent microscope. cells have emission
- excitation wavelengths of 495nm - 515nm for live cells, 528nm - 617nm for dead cells.

3.10 qPCR
M1 to M2 macrophage polarization for treatment with RA and MSC loaded electrospun
and EGDE crosslinked pullulan/gelatin scaffold using qPCR. M1and M2 markers were
assessed. M1 markers: TNF-α (Sinobiological, Beijing, China), IL1β (Sinobiological, Beijing,
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China). M2 markers: CCL22 (Biomol, Pompano Beach, FL), CCL18 (GeneCopoeia, Rockville,
MD). Macrophages were plated at 2e6 cells per well. 10μg scaffold was added to each
transwell with RA loaded at 5μg or 10μg and/or passage 4 MSCs loaded at 1e6 cell. Cells
were incubated for 2 days with treatment and then M1 and M2 markers expression was
assessed. After incubation cells were washed with PBS. Trizol reagent (Invitrogen,
Rockford, IL) was used to isolate RNA. NanoDrop 2000 spectrophotometer (Thermo
Fisher, Waltham, MA) was used to measure RNA concentration. Approximately 300ηg of
RNA was transcribed into cDNA using Applied Biosystems high-capacity cDNA reverse
transcription kit (Foster City, CA). SYBR Green PCR master mix (Applied Biosystems, Foster
City, CA) was used for qPCR setup, and StepOnePlus real time qPCR machine from Applied
Biosystems (Applied Biosystems, Foster City, CA) performed reaction and analysis.
Amplification reaction Setup: 95oC 5min for pre-denaturation, 50 cycles of [95 oC 20s, 60
oC

40s, 72 oC 20s], Melt curve. GAPDH was used as control to determine relative gene

expression. fold change was calculate using the formula: fold change = 2^- ΔΔCt.

3.11 Statistical Analysis
All data was compiled in Excel then transferred to JMP student edition 10 statistical
software from SAS. JMP was used to perform t tests for nanofiber diameter and all qPCR
assays. JMP was also used to perform two-way ANOVA on Scaffold Degradation and RA
release rate.
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CHAPTER IV
Results
4

4.1 Scaffold Composition
Pullulan is a linear, nonionic, water soluble exopolysaccharide composed of α-1,6linked maltotiose residues and produced by yeast like fungus Aureobasidium pullulans. It
is composed of 9 hydroxyl groups making it a highly modifiable compound. Pullulan is
useful in biomedicine because it is amenable to manipulation, non-toxic, biocompatible,
blood compatible, non-toxic, biodegradable has antioxidant properties. It also has other
properties such as being good mechanical strength and non-reducing and thermal
stability. Pullulan has been FDA approved for use as a food preservative due to its slow
digestibility and low-calorie count. Recent evidence supports pullulan as an ideal
therapeutic target for tissue engineering and wound healing [152], [219].
Pullulan and gelatin scaffolds have shown promising wound healing abilities.
Gelatin is a polypeptide derived from the hydrolysis of the collagen protein. Collagen is
an important component of the extracellular matrix of connective tissue. It is ideal for use
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in tissue engineering in scaffolds however it is not as easy to work with a gelatin. Gelatin
is a good alternative to collagen, the major downside is that it loses some of its mechanical
properties during the denaturing process, however crosslinking can improve its
mechanical properties. Gelatin is also less immunogenic than collagen. The polypeptide
arrangement of Gelatin provides a RGD motif which causes cellular attachment to the
gelatin and can be very useful in scaffolds. Gelatin can also signal differentiation, and
proliferation. Gelatin is FDA approved for use as a food additive and gelling agent as well
as recently for tissue engineering applications such as drug delivery, wound healing,
regeneration, as well as the food industry [27], [153], [241], [242], [257].
Pullulan and gelatin seem to be a good pair for wound repair, offering ROS
quenching and cellular attachment as well as being a potential vehicle for drug and
mesenchymal stem cell delivery. Therefore, we chose to use pullulan and gelatin as the
base for our scaffold. Previous studies have shown that pullulan and gelatin can improve
wound repair, and that cells such as MSCs can be loaded onto such a scaffold to promote
improved wound healing[15], [28], [152], [153]. We decided to electrospin pullulan and
gelatin which is an easy quick, cost effective and scalable method of creating scaffolds
that allows tailorable nanofiber diameter size and porosity [141], [286]. This is the firsttime gelatin/pullulan nanofibers have been successfully and verifiably produced. There is
one conference abstract describes an attempt to electrospin pullulan and gelatin,
however this is the first time it has been chemically confirmed [287].
After choosing our scaffold we tested the composition, degradation rate, and
release rate of several polymer combinations. We used combinations of 75% pullulan with
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0, 1:70 and 1:50 crosslinking as described in the methods. We also tested 50% pullulan
with 0, 1:70 and 1:50. To characterize molecular composition FTIR was performed on all
of these including with incorporation of 10μg of RA. As controls, RA, pullulan, and gelatin
were each tested, gelatin and pullulan in their powder form, and RA as a KBr pellet. FTIR
provides mostly qualitative data showing which materials were present. In each of our
samples we confirmed the presence of pullulan, gelatin and loaded drug. In our invitro
testing we had to choose one polymer which was 75% pullulan with 1:70 crosslinking,
which is why in Figure 6 we show the FTIR spectrum of only that sample. The 75% pullulan
with 1:70 crosslinking sample was decided upon based on degradation and drug release
observed. We had also tried using 1:100 crosslinker but it degraded to quickly and could
be used invitro.
FTIR analysis confirms gelatin and pullulan are both present in this scaffold (Figure
6a). The presence of gelatin can be seen by C = O stretching of amide I at 1630 and N-H
bending of amide II at 1520 [288]. The presence of pullulan can be seen by for C=O
stretching of sp3 Carbon hydrogen bond at 2900, C – O – H bending at 1340, C – O – C
stretching at 1140, α-(1,4)-D-glucosidic bonds at 928, α configuration of α-Dglucopyranose at 844, and α-(1,6)-D-glucosidic bonds at 755 [289], [290]. With the
confirmation of the scaffold composition next we tested to see if the crosslinker was still
present.
In Figure 6b we confirmed the presence of EGDE in the scaffold. EGDE can
chemically react with amino, carboxyl and hydroxyl functional groups. EGDE can be seen
by the presence of carbon nitrogen bonds at 852 and 1260 as well as an increased peak
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at 330 due to stretching of the hydroxyl group. The IR spectrum for EGDE was taken from
the “Spectral Database for Organ Compounds” and superimposed on or graph to
determine peak overlap. EGDE is a able to crosslink the hydroxyl groups on both pullulan
and gelatin as depicted in figure 3 [150], [151], [218]. EGDE has two reactive epoxide
functional groups which are highly reactive due to the strain existing in the epoxide ring.
The detection of RA determined using FTIR to ensure RA was being loaded in the
scaffold. RA is a reactive metabolite of vitamin A has several developmental and cellular
affects. RA binds to receptors in immune cell and is able to promotes differentiation of
myeloid cells into macrophages, reduce inflammation, and convert macrophages in M1
phenotype to M2 phenotype [14], [291]. After crosslinking the scaffold RA was added.
The carbon oxygen stretch vibrations at 1250 confirm the presence of RA in Figure 6c
[259]

a

50

b

Ethylene Glycol Diglycidyl Ether from the Spectral Database for Organic Compounds
http://sdbs.db.aist.go.jp/sdbs/cgi-bin/direct_frame_top.cgi

c

Figure 6: FTIR of pullulan, gelatin, and 75% pullulan/25% gelatin scaffold (a), FTIR of
75% pullulan/25% gelatin scaffold before and after crosslinking 1:70 EGDE in EtOH
(b), FTIR of 75% pullulan/25% gelatin scaffold crosslinked 1:70 EGDE in EtOH before
and after adding RA (c)
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Figure 7: Crosslinking Reaction of EGDE

4.2 Nanofiber Characterization
Each of the polymer nanofiber combinations were imaged using SEM. We looked at
100% pullulan, 75% pullulan and 50% pullulan (75% pullulan means 25% gelatin and so
on). The nanofibers were also crosslinked with EGDE 1:70 and 1:50 as in the FTIR. The
images shown in Figure 8 are similar visual between each sample. Nanofibers were seen
to be randomly distributed and monomodal. Images were then analyzed using Image J to
determine the diameter of the nanofibers as shown in Table 2. The diameter of the
nanofibers was between 300-370nm for each of the samples. There was a significant
increase in diameter as percentage of gelatin increased (Figure 8 a,b,c). 75% pullulan with
1:70 crosslinking trends to have the smallest diameter, and smaller diameter size implies
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increased space for drug loading, therefore, this presented evidence that it may be a good
polymer for drug delivery.

Figure 8: SEM images of nanofibers; 100% pullulan (a), 75% pullulan/25% gelatin (b),
50% pullulan/25% gelatin (c), 75% pullulan/25% gelatin with EGDE crosslinking 1:70
in EtOH 1:70 (d), 50% pullulan/25% gelatin with EGDE crosslinking 1:70 in EtOH (e),
75% pullulan/25% gelatin with EGDE crosslinking 1:50 in EtOH (f), 50% pullulan/25%
gelatin with EGDE crosslinking 1:50 in EtOH (g)
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Table 2: Nanofiber Diameter

4.3 Scaffold Degradation
Degradation testing was performed by incubating samples with Ringers solution,
which is an isotonic solution made of sodium chloride, potassium chloride, sodium
bicarbonate and calcium chloride. To recapitulate physiological conditions by incubating
samples in Ringer’s solution and incubating at 37oc with constant agitation. Ringers
solution is relatively like body fluids. RA was also added to the scaffolds and examined to
see if there was any noticeable effect, however there was no significant effect seen on
any of the samples. It was observed that most of the sample degraded after the first day,
however it slowed down considerably in the following days and weeks. The reason
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degradation was so high at the beginning and then slowed down considerably may have
been due to decrease in surface area of the polymer. As the polymer degraded the highly
porous scaffold may have shrunk reducing hydrolytic degradation of the polymers [292],
[293]. When we examined the degradation via ANOVA 75% pullulan compositions had
significantly less degradation compared to 50% pullulan compositions with a p value of
<0.0005 that they were different. We decided to go with the polymer that degraded the
least so that it would have a higher potential for prolonged drug delivery, therefore, we
chose to use 75% pullulan for our invitro studies.

100
90
75% 1:70 EGDE

80

75% 1:50 EGDE
75% 1:70 EGDE + 5ug RA

Percent Degraded

70

75% 1:50 EGDE + 5ug RA

60

75% 1:70 EGDE + 10ug RA
75% 1:50 EGDE + 10ug RA

50

50% 1:70 EGDE

40

50% 1:50 EGDE
50% 1:70 EGDE + 5ug RA

30

50% 1:50 EGDE + 5ug RA

20

50% 1:70 EGDE + 10ug RA
50% 1:50 EGDE + 10ug RA

10
0

Day 1

Day 3

Day 7

Day 14

Figure 9: Degradation of scaffold measured on day 1, 3, 7 and 14
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4.4 Drug Release
RA release rate was examined at 1h, 2h, 4h, 8h, 1 day, 3 days and 1 week by
collecting Ringer’s solution from the degradation test samples and testing absorbance at
316nm. Samples were either loaded with 5μg or 10μg of RA. Two concentrations of RA
were loaded in the scaffolds 5μg and 10μg. The majority of RA was released within the
first 24 hours. Comparing the samples via Two-Way ANOVA, RA is seen to have less
release of 1:70 crosslinking than 1:50 crosslinking with a p value of <0.0001. 75% and 50%
RA show similar release rates, so composition of pullulan to gelatin does not seem to
affect release rate. Since RA has a lower release rate the 1:70 crosslinking we decided to
go with this with the idea that drug treatment may be extended.
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Figure 10: Release rate of RA from scaffold measured at 1h, 4h, 8h, 72h, 168h

4.5 M1 Macrophage Viability and Expression
The inflammatory M1 phenotype causes cell death and delayed healing. Therefore,
converting M1 macrophages into M2 may be able to ameliorate inflammatory disorders
in which the M1 phenotype is overexpressed such as in chronic wounds. To assess
treatment of RA and MSC loaded nanofibrous scaffold to convert M1 macrophages from
M1 to M2 phenotype, we performed qPCR and determined M1 and M2 inflammatory
marker expression. We chose to use THP-1 cells to derive our macrophages for our invitro
studies. THP-1 cells are commonly used to study macrophage functions. We used a
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tradition method of using PMA to differentiate the promonocytic THP-1 cells into
macrophages as has been well discussed in literature [4]. ThP-1 derived macrophages
were then incubated with LPS and IFN-γ to induce M1 phenotype. Prior to doing qPCR
with the treatments we first tested the length of time needed to incubate LPS and IFN-γ
before M1 markers were expressed and to determine how the cells did with the
treatment using a live/dead ethidium/calcein kit. The Viability test (Figure 11) showed a
large increase in cells incubated for 2 or three days. qPCR however did not show any
differences between 1, 2 or 3 days of treatment with LPS/IFNY (Figure 12 a-c). Important
to note is that the M2 marker CCL18 was overly expressed (data not shown). We were
using a large amount of LPS to stimulate M1 macrophage phenotype which can cause this
to occur [4]. Since there was less cell death at day 1 we chose this for M1 polarization.
Next treatment efficacy was assessed.
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Figure 11: Live/dead assay showing NT (a-c), 1 day of LPS/IFN-γ treatment (d-f), 2 day
of LPS/IFN-γ treatment (g-i), 3 day of LPS/IFN-γ treatment (j-l). live cells are depicted
in green (a, d, g, j), dead cells are depicted in red (b, e, h, k), and merge (c, f, I, l)
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4.6 Retinoic Acid and MSCs Promote M1 to M2 Conversion
To investigate the ability for the RA and ADMSCs to re-polarize macrophages we
then conducted invitro tests by incubating the macrophages with scaffolds, then assessed
M1 and M2 expression patterns. IL1β and TNFα were the M1 makers tested, and CCl22 is
the M2 marker examined. Macrophages are plastic cells and can switch polarity between
M1 and M2 phenotype due to environmental factors. Both RA and MSC’s have been
shown to modulate the response in previous research. In our study RA significantly
decreases M1 polarity marker IL-1β, with a p value of 0.0197 (Figure 12 d-f). The
pullulan/gelatin scaffold was able to significantly decrease all M1 markers and
significantly increase all M2 markers. 10μg RA loaded scaffold and MSC loaded scaffold
both have increased CCL22, while all treatments can significantly decreased IL1-β, and
TNF-α compared to NT (Figure 8 g-i). All treatments were able to decrease inflammatory
markers TNFα and IL-1β. Treatment with both mesenchymal stem cells and retinoic
seemed the least effective to promote inflammatory cytokine CCL22 and there was no
significant difference from the NT. Scaffold, scaffold with MSCs and scaffold loaded with
RA were however able to significantly improve CCL22 expression. Perhaps RA is
interacting in a way with MSCs that causes a reduction in CCL22 expression. This study
reveals modulation of macrophages to M2 phenotype which could promote alleviation of
several diseases. Future studies should examine the effect of these different
combinations in vivo.
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Figure 12: qPCR of 1 day, 2 days and 3 days treatment of macrophages with 100ng
M1 to M2 transitioning effect of 100ηg/mL LPS and 100 ηg/mL IFN-γ (a-c), qPCR of
RA in vitro on M1 to M2 transition (d-f), qPCR of scaffolds loaded with RA and/or
MSCs on M1 to M2 transition (g-i)

4.7 CONCLUSIONS
In summary, electrospun scaffolds composed of pullulan and gelatin nanofibers
were successfully fabricated and crosslinked with EGDE, and loaded with RA. This work
demonstrates the ability of RA, MSCs and the scaffold by itself to induce a shift from a M1
into an M2 phenotype in activated macrophages. Inflammatory markers IL1β and TNFα
were decreased in all samples. All cells treated with RA and the scaffold containing MSCs
were able to increase the M2 marker CCL22. MSCs and RA treated wells however did not
have significantly improved CCL22. Further examination should be done to determine the
reason why there was a CCL22 decrease in cells treated with both RA and MSCs. These
tests verify the feasibility of combining this 75% pullulan and 25% gelatin electrospun
scaffold with RA and MSCs to convert M1 macrophages into M2 phenotype, thus having
potentially as novel therapeutic to reduce inflammatory diseases such as chronic wounds.
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